We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byPrecious Ellenwood
Modified about 1 year ago
Montalescot G, et al. Lancet 2009;373:723-31
Trial profile Montalescot G, et al. Lancet 2009;373:723-31
Baseline characteristics of STEMI cohort, by drug allocation and type of PCI Montalescot G, et al. Lancet 2009;373:723-31
Major efficacy and safety endpoints at 30 days Montalescot G, et al. Lancet 2009;373:723-31
Major efficacy and safety endpoints at 15 months Montalescot G, et al. Lancet 2009;373:723-31
Kaplan-Meier curves for selected endpoints Montalescot G, et al. Lancet 2009;373:723-31
Trial profile Fox K et al. Lancet 2008;372:
TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,
Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.
TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)
Trial profile Mann JF et al. Lancet 2008;372:
Sibbing D, et al. J Am Coll Cardiol 2009;53:
Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
A Randomized, Double-blind, Placebo-controlled Trial of Intravenous Erythropoietin in Patients with ST-Segment Elevation Myocardial Infarction – Primary.
ReoPro ® in NSTEMI and STEMI Trials Harald Vangerow, MD Clinical Research Physician Eli Lilly UK.
Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.
Montalescot G et al. Lancet 2008;372:1-9. Mid- and long-term outcomes of STEMI patients treated with prasugrel, compared with clopidogrel and undergoing.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Frequency of Clostridium difficile infection (CDI) transmission via ward contact with a known case Retrospective, observational study (22 months; 1 laboratory.
Enoxaparin in primary PCI From FINESSE to ATOLL G. Montalescot Institut de Cardiologie Pitié-Salpêtrière Hospital Paris, France The FINESSE Trial is supported.
Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter,
Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:
Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosis ALBION.
HORIZONS –AMI A Prospective, Multicenter Randomized Trial of Heparin Plus GPIIb/IIIa Inhibitors vs. Bivalirudiin STEMI: Final 3-year results from the HORIZONS-
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.
ELITE - II Study Design 60 yrs; NYHA II - IV; EF 40 % ACEI naive or 7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.
Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.
Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials by Michel D. Ferrari, Krista I. Roon, Richard B.
Bonferroni: Friend or Foe? Multiple Testing in Cardiovascular Medicine Dhruv S. Kazi, MD, MSc AHA Cardiovascular Outcomes Research Fellow Stanford University.
Prehospital Fibrinolysis with Double Antiplatelet Therapy in Acute ST-Elevation Myocardial Infarction: The Clarity Ambulance Substudy Prehospital Fibrinolysis.
David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
FREEDOMS II TRIAL. Study Design 24-month, RCT of fingolimod 0.5 mg and 1.25 mg vs placebo – 3 years into the study, 1.25 mg discontinued and patients.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.
Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia ( TASTE trial) Ole Fröbert, MD, PhD - on behalf of the TASTE investigators Departement.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
PPAR activation Clinical evidence. Evolution of clinical evidence supporting PPAR activation and beyond Surrogate outcomes studies Large.
Trans-Radial Approach for STEMI Evolution of TRA in single center Rationale behind increased TRA use Progression to use in STEMI Data analysis of STEMI.
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Comparative Utility of the BESTest, Mini-BESTest, and Brief-BESTest for Predicting Falls in Individuals With Parkinson Disease: A Cohort Study by Ryan.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
© 2017 SlidePlayer.com Inc. All rights reserved.